Bcr-Abl inhibitors paved the way of targeted therapy epoch. Imatinib was the first tyrosine
kinase inhibitor to be discovered with high specificity for Bcr-Abl protein resulting from t (9 …

Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases
expressed on the cell membrane that play crucial roles in both developmental and adult …

All successful cancer therapies are limited by the development of drug resistance. The
increase in the understanding of the molecular and biochemical bases of drug efficacy has …

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …

The human FGF receptors (FGFRs) play critical roles in various human cancers, and several
FGFR inhibitors are currently under clinical investigation. Resistance usually results from …

Introduction: Because of their important roles in disease and excellent 'druggability', kinases
have become the second largest drug target family. The great success of the BCR-ABL …

Beginning with imatinib a decade ago, therapy based on targeted inhibition of the BCR-ABL
kinase has greatly improved the prognosis for chronic myeloid leukemia (CML) patients. The …

Chromosomal translocation occurs in some cancer cells, which results in the expression of
aberrant oncogenic fusion proteins that include BCR‐ABL in chronic myelogenous leukemia …

BCR:: ABL1 tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML)
from a lethal condition into a chronic ailment. With optimal management, the survival of CML …

In 2012, ponatinib (Iclusig®), an orally available pan-BCR-ABL tyrosine kinase inhibitor
(TKI) developed by ARIAD Pharmaceuticals, Inc., was approved by the US Food and Drug …